Loading…
← CockpitCompetitor Analysis › 2160.T GNI Group Ltd.Open in the cockpit ↗

GNI Group Ltd.2160.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Biotechnology

Japan/China biopharma developer of fibrosis treatments, with a Phase III liver-fibrosis drug via Chinese subsidiary Beijing Continent.

≈ A Japan-listed biotech with its main pipeline running through a Chinese subsidiaryMomentum laggard 9
Mkt cap
$903M
US dollars, full cap
Free float
85%
of shares outstanding
$/day
$60.9M
20-day average traded
Fwd P/E
143.0×
forward earnings
ROIC−WACC
-13.7 pp
WACC 10.6%
Hurdle
n/a
no reverse DCF
Next earnings
91 days
17 Feb 2027
Close · JPY¥2,228
1D-2.8%
1W+4.1%
1M-21.8%
3M-24.1%
6M-24.6%
YTD-7.6%
1Y-12.0%
ATR %10.4%
52w lowhigh40.4% off high

What GNI does

Japan/China biopharma developer of fibrosis treatments, with a Phase III liver-fibrosis drug via Chinese subsidiary Beijing Continent.

Earns mostly from selling Etuary, its pirfenidone drug for lung fibrosis, in China, with those sales funding development of F351, its liver-fibrosis candidate in late-stage trials. Most operations and revenue sit in China through its subsidiary, though the parent is listed in Japan.

In one line: A Japan-listed biotech with its main pipeline running through a Chinese subsidiary.

Products and services

  • ETUARY (pirfenidone, lung fibrosis)
  • F351 (liver fibrosis, Phase III China)
  • Wound-care/orthobiologics products

Customers

  • Hospitals/patients in Japan and China
  • Licensing partners

Where it sits in the supply chain

  • Health Care
  • Biopharmaceuticals
  • Fibrosis/rare-disease drug development

What could go right

  • China Phase III trial progress/approval
  • 2026 acquisition of Ayumi Pharmaceutical

What could go wrong

  • Binary clinical trial outcome risk
  • China regulatory/reimbursement uncertainty

Moat: narrow (IP / patents, regulatory licence). Late-stage fibrosis drug candidates and a China-approved subsidiary give a scarce pipeline position.

Headquarters: Tokyo, Japan · Founded: 1990 · Employees: 990

Named competitors

GNI at a glance

Size GNI (2160.T) is a Japan Health Care company (Biotechnology) with a market value of $903M, the 781st largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥2,228 on 18 Nov 2026.

Performance Over six months the shares fell 24.6%, against -16.5% for the median peer and -1.4% for the Japan market (cap-weighted) — 8th lowest of 21 in its peer set.

Growth Revenue grew 44.4% over the last twelve months (peer median +1.1%); the operating margin is -21.2% (peer median -45.3%).

Valuation It trades at 143.0× forward earnings against a peer median of 29.2× (most expensive of 7).

Capital Return on invested capital runs 13.7 points below its cost of capital (10.6% WACC).

Next results Next results expected around 17 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010012014021 May 202621 Aug 202618 Nov 2026Peer median 842160.T 83
Six months, rebased to 100: GNI against the median of its 20 peers (local-currency closes).

GNI financials

Reported figures in JPY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥37.2B¥26.8B¥23.6B¥26.0B¥17.4B
Revenue growth—+14%-9%+49%—
Gross profit¥23.5B¥20.0B¥18.0B¥22.4B¥14.7B
EBITDA-¥5.64B-¥1.16B¥437M¥5.19B¥1.76B
Net income-¥7.79B-¥4.24B¥1.10B¥8.09B¥389M
Free cash flow-¥10.2B-¥2.74B-¥3.69B¥5.28B-¥580M
Capital expenditure¥4.29B¥1.56B¥1.54B¥2.08B¥1.94B
Total debt¥83.9B¥22.2B¥22.7B¥18.8B¥10.2B

Quarterly statements and history in the cockpit →

GNI competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%-20%0%300841ODTX6882536001954587VSTMOXB688276SGPMGTXINBXANRO688526300482GLUESNDX96069887IVA2160.T6-month return →1-month return →
Up and to the right = strong over both horizons. GNI is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%50×100×150×30084168825360019545876885263004822160.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. GNI is the large dot.

GNI competitors and peer comparison

Head to head with its named competitors (2160.T vs 2162.HK vs 4507.T)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
GNI 2160.T$903M-25%+44%-21%143.0×n/a
Keymed Biosciences 2162.HK$2.39B+7%0%-73%18.2×n/a
Shionogi & 4507.T$17.6B+3%+46%29%11.8×0.2%

How GNI compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

GNI against its 20 peers (data as of 18 Nov 2026)
Measure2160.TPeer medianRank in peer set
1-month return-21.8%-8.8%6th lowest of 21
6-month return-24.6%-16.5%8th lowest of 21
Distance from 52-week high-40.4%-41.8%10th highest of 21
Revenue growth (TTM)+44.4%+1.1%4th highest of 18
Operating margin-21.2%-45.3%9th highest of 19
Forward P/E143.0×29.2×most expensive of 7
ROIC minus cost of capital-13.7 pp-8.9 pp4th lowest of 13

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
GNI 2160.TJapan$903M-25%+44%-21%143.0×n/an/a
Chengdu Kanghua Biological Products Co. Td Class 1 300841.SZChina$909M-15%0%22%21.6×9.2%+2.3%
Odyssey Therapeutics ODTXUnited States$912M+12%-33%-5,415%n/an/an/a
Innovita Biological Technology 688253.SSChina$915M-28%-28%11%92.6×39.6%-16.6%
China Animal Husbandry Industry 600195.SSChina$921M-16%+1%2%41.5×6.1%+4.4%
Peptidream 4587.TJapan$878M-3%+14%-18%29.9×n/an/a
Verastem VSTMUnited States$866M+66%+650%-194%n/an/an/a
Oxford BioMedica OXB.LUnited Kingdom$841M-15%+16%-18%n/an/an/a
Changchun BCHT Biotechnology 688276.SSChina$992M-2%+2%-29%n/an/an/a
SpyGlass Pharma SGPUnited States$993M+36%n/an/an/an/an/a
MeiraGTx MGTXUnited States$813M-13%+1,366%44%n/an/an/a
Inhibrx Biosciences INBXUnited States$1.02B-37%+43%-6,287%n/an/an/a
Alto Neuroscience ANROUnited States$1.04B+25%n/an/an/an/an/a
Wuhan Keqian Biology 688526.SSChina$780M-24%-22%20%19.4×7.8%+2.4%
Guangzhou Wondfo Biotech 300482.SZChina$1.05B-18%-24%-2%28.4×14.3%-5.8%
Daan Gene 002030.SZChina$1.05B-17%+1%-81%n/a4.8%-32.3%
Monte Rosa Therapeutics GLUEUnited States$775M-51%-61%-214%n/an/an/a
Syndax Pharmaceuticals SNDXUnited States$771M-57%+160%-62%n/an/an/a
Duality Biotherapeutics 9606.HKHong Kong$1.06B-58%-5%-181%n/an/an/a
Nanjing Leads Biolabs 9887.HKHong Kong$764M-50%n/a-108%n/an/an/a
Inventiva IVA.PAFrance$763M-36%-100%-307,063%n/an/an/a

Questions

Who are GNI's main competitors?
Named competitors: Chi-Med (Hutchmed) (2162.HK), Shionogi (4507.T), Boehringer Ingelheim (private) (private or unlisted). The cockpit's measured peer set (industry) also includes Chengdu Kanghua Biological Products Co. Td Class 1 (300841.SZ), Odyssey Therapeutics (ODTX), Innovita Biological Technology (688253.SS), China Animal Husbandry Industry (600195.SS), Peptidream (4587.T), Verastem (VSTM).
Is GNI expensive compared with its peers?
On forward p/e it trades at 143.0× against a peer median of 29.2×, most expensive of 7 in its peer set.
How has GNI stock performed?
Over six months to 18 Nov 2026 the shares returned -24.6% against -16.5% for the median peer; over one year -12.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.